Sandra Calvin - 25 Nov 2024 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
25 Nov 2024
Net transactions value
-$31,208
Form type
4
Filing time
25 Nov 2024, 21:00:49 UTC
Previous filing
02 Feb 2024
Next filing
27 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise $190,050 +15,000 +29% $12.67 67,017 25 Nov 2024 Direct
transaction TVTX Common Stock Sale $221,258 -12,090 -18% $18.30 54,927 25 Nov 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -15,000 -50% $0.000000 15,000 25 Nov 2024 Common Stock 15,000 $12.67 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person in order to cover the tax withholding obligation and payment of the exercise price in connection with the partial exercise of a stock option granted to the Reporting Person on January 2, 2015 with an upcoming expiration date of January 2, 2025.
F2 The weighted average sale price for the transaction reported was $18.3009, and the range of prices were between $18.27 and $18.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3 The stock option is fully vested and exercisable.